59489-74-6Relevant academic research and scientific papers
Iridium-Catalyzed Asymmetric Hydrogenation of Tosylamido-Substituted Pyrazines for Constructing Chiral Tetrahydropyrazines with an Amidine Skelton
Higashida, Kosuke,Nagae, Haruki,Mashima, Kazushi
, p. 3949 - 3954 (2016)
Dinuclear triply chloro-bridged iridium(III) complexes bearing chiral diphosphine ligands catalyze the asymmetric hydrogenation of tosylamido-substituted pyrazines to give the corresponding chiral tetrahydropyrazines with an amidine skeleton in high yield and with high enantioselectivity. Addition of N,N-dimethylanilinium bromide enhanced the catalytic activity of the iridium complexes and also increased the enantioselectivity of the products by trapping the hydrogenated amine products with HBr from N,N-dimethylanilinium bromide. The amidine skeleton of the products could be transformed to give chiral piperazinones and piperazines without loss of enantioselectivity. (Figure presented.).
With anti-tumor activity of the amide compound and use thereof
-
Paragraph 0062; 0063; 0064, (2017/02/09)
The invention belongs to the technical field of medicines and particularly relates to amide compounds with antitumor activity and an application of the amide compounds. The amide compounds are as shown in the general formula (I), wherein R1 and R2 can be same or different and are respectively and independently selected from hydrogen, halogen, a cyan, hydroxyl, halogenated alkyl, alkoxy, alkoxylalkyl, alkylamino or alkylaminoalkyl; R3 is triazole, 1, 3, 4-oxa-diazole, carbonyl and respective corresponding electro-withdrawing or electron donating substituent groups; and X is carbon or nitrogen atoms. A pharmacological activity result of the amide compounds provided by the invention shows that the amide compounds have favorable inhibiting effect for tumor cell strains.
COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
-
Page/Page column 62-63, (2012/02/01)
Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically ac
